Last reviewed · How we verify
local tetracycline
local tetracycline is a Matrix metalloproteinase inhibitor Small molecule drug developed by The Forsyth Institute. It is currently in Phase 3 development for Chronic periodontitis, Periodontal disease with inflammation.
Local tetracycline delivery inhibits matrix metalloproteinases and reduces inflammation in periodontal tissues.
Local tetracycline delivery inhibits matrix metalloproteinases and reduces inflammation in periodontal tissues. Used for Chronic periodontitis, Periodontal disease with inflammation.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | local tetracycline |
|---|---|
| Sponsor | The Forsyth Institute |
| Drug class | Matrix metalloproteinase inhibitor |
| Target | Matrix metalloproteinases (MMPs) |
| Modality | Small molecule |
| Therapeutic area | Dentistry / Periodontics |
| Phase | Phase 3 |
Mechanism of action
Tetracyclines, particularly at sub-antimicrobial doses, inhibit matrix metalloproteinases (MMPs) that degrade collagen and extracellular matrix in periodontal disease. This mechanism reduces tissue destruction and inflammation without requiring systemic antibiotic levels. Local delivery to the periodontal pocket maximizes therapeutic effect while minimizing systemic exposure.
Approved indications
- Chronic periodontitis
- Periodontal disease with inflammation
Common side effects
- Local irritation or discomfort at application site
- Tooth sensitivity
- Gingival erythema
Key clinical trials
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (PHASE2)
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Collaborative Urological Prosthetics Investigation Directive Research Group (EARLY_PHASE1)
- Non-surgical Treatment of Peri-implantitis Using Chitosan Brush and Tetracycline Slurry (PHASE4)
- Comparing the Efficacy of Metronidazole and Minocycline Gels for the Treatment of Diabetic Periodontitis Patients (NA)
- Non-instrumentation Root Canal Treatment of Primary Molars (NA)
- Parrying the Pitfalls of PrEP: Project PEACH (PHASE4)
- Management of Ventilation Acquired Pneumonia Caused by Pseudomonas and Acinetobacter Organisms in a Pediatric Center (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- local tetracycline CI brief — competitive landscape report
- local tetracycline updates RSS · CI watch RSS
- The Forsyth Institute portfolio CI
Frequently asked questions about local tetracycline
What is local tetracycline?
How does local tetracycline work?
What is local tetracycline used for?
Who makes local tetracycline?
What drug class is local tetracycline in?
What development phase is local tetracycline in?
What are the side effects of local tetracycline?
What does local tetracycline target?
Related
- Drug class: All Matrix metalloproteinase inhibitor drugs
- Target: All drugs targeting Matrix metalloproteinases (MMPs)
- Manufacturer: The Forsyth Institute — full pipeline
- Therapeutic area: All drugs in Dentistry / Periodontics
- Indication: Drugs for Chronic periodontitis
- Indication: Drugs for Periodontal disease with inflammation
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing